Literature DB >> 7768358

Soluble interleukin-6 (IL-6) receptor augments central effects of IL-6 in vivo.

B Schöbitz1, G Pezeshki, T Pohl, U Hemmann, P C Heinrich, F Holsboer, J M Reul.   

Abstract

The pleiotropic cytokine interleukin-6 (IL-6) controls both the peripheral and central components of the acute-phase response. These activities are mediated via the IL-6 membrane receptor, but probably also via agonistic soluble IL-6 receptors (sIL-6Rs). In the present study we conducted dose-response experiments with rats that were intracerebroventricularly i.c.v.) injected with recombinant human IL-6 and sIL-6R and determined body temperature, locomotor activity, food intake, and water consumption using radiotelemetry and continuous recordings of feeding and drinking. IL-6 injected i.c.v. at 1, 10, and 100 ng increased body temperature and decreased locomotor activity and food intake, but it did not affect water consumption. When 10 ng sIL-6R, which lacked detectable biological activity, was injected i.c.v. 1 h before 1 ng IL-6, the central effects of IL-6 were enhanced and prolonged, and this was not due to endotoxin contamination of the recombinant proteins. Our data suggest that IL-6 plays an important role in the regulation of body temperature, general activity, and food intake in sick animals. Moreover, we have shown for the first time that it is possible to potentiate the effects of a mediator in vivo by administration of the corresponding receptor, which is a novel pharmacological tool for increasing receptor capacity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7768358     DOI: 10.1096/fasebj.9.8.7768358

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  38 in total

1.  Interleukin-6 trans-signaling in the senescent mouse brain is involved in infection-related deficits in contextual fear conditioning.

Authors:  Michael D Burton; Rodney W Johnson
Journal:  Brain Behav Immun       Date:  2011-10-29       Impact factor: 7.217

2.  Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity.

Authors:  C Toniatti; A Cabibbo; E Sporena; A L Salvati; M Cerretani; S Serafini; A Lahm; R Cortese; G Ciliberto
Journal:  EMBO J       Date:  1996-06-03       Impact factor: 11.598

3.  Cytokines and soluble CD4 and CD8 molecules in rheumatoid arthritis: relationship to systematic vasculitis and microvascular capillaroscopic abnormalities.

Authors:  A Kuryliszyn-Moskal
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

4.  Construction and characterization of a replication-deficient adenovirus expressing rat-soluble interleukin-6 receptor.

Authors:  V Thibault; B Terlain; F L Graham; J Gauldie
Journal:  Mol Med       Date:  1997-08       Impact factor: 6.354

5.  IL12Rβ1ΔTM is a secreted product of il12rb1 that promotes control of extrapulmonary tuberculosis.

Authors:  Aurelie A Ray; Jeffrey J Fountain; Halli E Miller; Andrea M Cooper; Richard T Robinson
Journal:  Infect Immun       Date:  2014-11-17       Impact factor: 3.441

Review 6.  IL-6 as a keystone cytokine in health and disease.

Authors:  Christopher A Hunter; Simon A Jones
Journal:  Nat Immunol       Date:  2015-05       Impact factor: 25.606

7.  Profile of soluble cytokine receptors in Crohn's disease.

Authors:  T Gustot; A Lemmers; E Louis; C Nicaise; E Quertinmont; J Belaiche; S Roland; A Van Gossum; J Devière; D Franchimont
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

8.  IL-6-trans-signalling increases rapid-eye-movement sleep in rats.

Authors:  Ulrike May; Thomas Schiffelholz; Paul Christian Baier; James M Krueger; Stefan Rose-John; Jürgen Scheller
Journal:  Eur J Pharmacol       Date:  2009-04-19       Impact factor: 4.432

9.  Influence of hypothalamic IL-6/gp130 receptor signaling on the HPA axis response to chronic stress.

Authors:  Milena Girotti; Jennifer J Donegan; David A Morilak
Journal:  Psychoneuroendocrinology       Date:  2012-12-04       Impact factor: 4.905

Review 10.  Elucidating the unexplained underperformance syndrome in endurance athletes : the interleukin-6 hypothesis.

Authors:  Paula Robson
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.